Farmakoterapia w Psychiatrii i Neurologii

Full text

4/2020 vol. 36
Review paper

Inflammatory process as an etiological and prognostic factor of stroke and the goal of potential treatment strategies

Agnieszka Kraśniej-Dębkowska 1
,
Maciej Śnieżyński 1
,
Anna Członkowska 1
  1. Institute of Psychiatry and Neurology, 2nd Department of Neurology
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (4), 297–311
Data publikacji online: 2021/12/06
Article file
03R_IPiN_FARM_2020-4C_AKC.pdf
  1. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11 (5): 1223–1230.
  2. Anrather J, Iadecola C. Inflammation and Stroke: An Overview. Neurotherapeutics 2016; 13: 661–670.
  3. Banach M, Markuszewski L, Grzegorczyk J, Jegier B. Rola zapalenia w patogenezie miażdżycy. Przegl Epidemiol 2004; 58: 663–670.
  4. Barer DH, Cruickshank JM, Ebrahim SB, Mitchell JRA. Low dose β blockade in acute stroke (“BEST” trial): An evaluation. Br Med J (Clin Res Ed) 1988; 296(6624): 737–741.
  5. Barreto GE, White RE, Ouyang Y, Xu L, Giffard RG. Astrocy tes: Targets for Neuroprotection in Stroke. Cent Nerv Syst Agents Med Chem 2012; 11: 164–173.
  6. Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Pro-inflammatory and anti-inflammatory cytokines in acu te ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008; 41(16–17): 1330–1334.
  7. Bobinger T, Manaenko A, Burkardt P, Beuscher V, Sprügel MI, Roeder SS et al. Siponimod (BAF-312) Attenuates Perihe morrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke 2019; 50 (11): 3246–3254.
  8. Całkosiński I, Dobrzyński M, Całkosińska M, Seweryn E, Bronowicka-Szydełko A, Dzierzba K et al. Charakterysty ka odczynu zapalnego. Postępy Hig Med Dosw 2009; 63: 395–408.
  9. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F et al. The early systemic prophylaxis of in-fection after stroke study: a randomized clinical trial. Stroke 2005; 36(7): 1495–1500.
  10. Członkowska A, Cyrta B, Korlak J. Immunological observa tions on patients with acute cerebral vascular disease. J Neu rol Sci 1979; 43(3): 455–464.
  11. d’Audigier C, Cochain C, Rossi E, Gue ́ rin CL, Bie`che I, Blan dinie`res A et al. Thrombin receptor PAR-1 activation on en dothelial progenitorcells enhances chemotaxis-associated genes expressionand leukocyte recruitment by a COX-2-de pendent mechanism. Angiogenesis 2015; 18: 347–359.
  12. Dziedzic T, Slowik A, Pera J, Szczudlik A. Beta-blockers re duce the risk of early death in ischemic stroke. J Neurol Sci 2007; 252(1): 53–56.
  13. Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, pla cebo-controlled, double-blind phase 2 trial. Lancet Neurol 2017; 16(3): 217–226.
  14. Ercan M, Firtina S, Konukoglu D. Comparison of plasma viscosity as a marker of endothelial dysfunction with ni tric oxide and asymmetric dimethylarginine in subjects with dyslipidemia. Clin. Hemorheol Microcirc 2014; 57(4): 315–323.
  15. Fu Y, Liu Q, Anrather J, Shi FD. Immune interventions in stroke. Nat Rev Neurol 2015; 11: 524–535.
  16. Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li YJ et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A 2014; 111 (51): 18315-18320.
  17. Gromadzka G, Sarzynska-Dlugosz I, Czlonkowska A. IL1RN intron 2 polymorphism caused by variable number tandem repeats is associated with 1-year outcome in patients with ischaemic stroke. J Neurol Neurosurg Psychiatry 2007; 78(2): 183–186.
  18. Jarząbek K, Sobczyk A, Sobczyk W, Łabuzek K, Belowski D, Gabryel B. Koncepcja niestabilnej blaszki miażdżycowej i farmakologiczne strategie terapeutyczne. Chirurgia Polska 2015; 17(1–2): 49–68.
  19. Jenny NS, Callas PW, Judd SE, McClure LA, Kissela B, Zakai NA et al. Inflammatory cytokines and ischemic stroke risk: The REGARDS cohort. Neurol 2019; 92(20): 2375–2384.
  20. Karliński M, Bembenek J, Grabska K, Kobayashi A, Baranow ska A, Litwin T et al. Routine serum C-reactive protein and stroke outcome after intravenous thrombolysis. Acta Neurol Scand 2014; 130: 305–311.
  21. Kelly P, Weimar C, Lemmens R, Murphy S, Purroy F, Arsovska A, NM Bornstein et.al. Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE) – study protocol for a randomised controlled trial. Eur Stroke J 2020; 0: 1-7.
  22. Koennecke HC, Belz W, Berfelde D, Endres M, Fitzek S, Ha miltonet F et al. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology 2011; 77: 965–972.
  23. Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): An Adaptive Dose-Response Study of UK-279,276 in Acute Ischemic Stroke. Stroke 2003; 34: 2543–2548.
  24. Kranzhofer R, Schmidt J, Pfeiffer CA, Hagl S, Libby P, Kübler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623–1629.
  25. Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on me chanisms of action and therapeutic uses. Semin Arthritis Rheum 2015; 45(3): 341–350.
  26. Libby P, Ridker P, Maseri A. Inflammation and Atheroscle rosis. Circulation 2002; 105: 1135–1143.
  27. Machado-Pereira M, Santos T, Ferreira L, Bernardino L, Fer reira R. Anti-Inflammatory Strategy for M2 Microglial Pola rization Using Retinoic Acid-Loaded Nanoparticles. Mediat Inflamm 2017; 2017 (Article: 6742427): 1–11.
  28. Maestrini I, Strbian D, Gautier S, Haapaniemi E, Mo ulin S, Sairanen T et al. Higher neutrophil counts beforethrombolysis for cerebral ischemia predict worse outcomes. Neurol 2015; 85(16): 1408–1416.
  29. Majid A. Neuroprotection in Stroke: Past, Present, and Futu re. ISRN Neurology 2014; 2014 (Article: 515716): 1–17.
  30. Manduteanu I, Simionescu M. Inflammation in atherosc lerosis: A cause or a result of vascular disorders? J Cell Mol Med 2012; 16: 1978–1990.
  31. Meisel C, Meisel A. Suppressing immunosuppression after stroke. N Eng J Med 2011; 365(22): 2134–2136.
  32. Mertens JC, Leenaerts D, Brouns R, Engelborghs S, Leven M, De Deyn PP et al. Procarboxypeptidase U (proCPU, TAFI, proCPB2) in cerebrospinal fluid during ischemic stroke is as sociated with stroke progression, outcome and blood-brain barrier dysfunction. J Thromb Haemost 2018; 16: 342–348.
  33. Montaner J, Fernandez-Cadenas I, Molina CA, Ribo M, Hu ertas R, Rosell A et al. Poststroke C-reactive protein is a po werful prognostic tool among candidates for thrombolysis. Stroke 2006; 37: 1205–1210.
  34. Morris RS, Jones PS, Alawneh JA, Hong YT, Fryer TD, Aigbirhio FI et al. Relationships between selective neuronal loss and microglial activation after ischaemic stroke in man. Brain 2018; 141: 2098–2111.
  35. Mracsko E, Veltkamp R. Neuroinflammation after intra cerebral hemorrhage. Front Cell Neurosci 2014; 8(Article 388): 1–13.
  36. Palasik W, Popow J, Lechowicz W, Fiszer U, Czlonkowska A. Prophylactic administration of intravenous immunoglo bulins in the early stage of ischemic stroke. Med Sci Monit 1999; 5(3): 528–532.
  37. Pasierski T, Andziak P. Rozwój i regresja miażdżycy. W: An giologia. Pasierski T, Gaciong Z, Torbicki A, Szmidt J (red.) Wyd. Lekarskie PZWL 2004; 50–58.
  38. Pradillo JM, Denes A, Greenhalgh AD, Boutin H, Drake C, McColl BW et al. Delayed administration of interleukin-1 receptor antagonist reduces ischemic brain damage and inflammation in comorbid rats. J Cereb Blood Flow Metab 2012; 32(9): 1810–1819.
  39. Reinink H, de Jonge JC, Bath PM, van de Beek D, Berge E, Borregaard S et al. PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, cli nical trial with blinded outcome assessment. Eur Stroke J 2018; 3: 291–298.
  40. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory therapy with ca nakinumab for atherosclerotic disease. N Eng J Med 2017; 377(12): 1119–1131.
  41. Ross R. Atherosclerosis – An inflammatory disease. N Engl J Med 1999; 340: 115–126.
  42. Sherman D, Bes A, Easton JD, Hacke W, Kaste M, Polmar SH et al. Use of anti-ICAM-1 therapy in ischemic stroke: Results of the enlimomab acute stroke trial. Neurology 2001; 57: 1428–1434.
  43. Shi K, Tian DC, Li ZG, Ducruet AF, Lawton MT, Shi FD. Glo bal brain inflammation in stroke. Lancet Neurol 2019; 18: 1058-1066.
  44. Schroeter M, Schiene K, Kraemer M, Hagemann G, Weigel H, Eysel UT et al. Astroglial responses in photochemically induced focal ischemia of the rat cortex. Exp Brain Res 1995; 106: 1–6.
  45. Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I et al. Peroxiredoxin family proteins are key initia tors of post-ischemic inflammation in the brain. Nat Med 2012; 18(6): 911–917.
  46. Stoll G, Nieswandt B. Thrombo-inflammation in acute ischa emic stroke – implications for treatment. Nat Rev Neurol 2019; 15(8): 473–481.
  47. Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP et al. Efficacy and safety of low-dose colchicine after my ocardial infarction. N Eng J Med 2019; 381(26): 2497–2505.
  48. Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol 2014; 11: 443–457.
  49. Thiel A, Radlinska BA, Paquette C, Sidel M, Soucy JP, Schir rmacher R et al. The temporal dynamics of poststroke neu roinflammation: a longitudinal diffusion tensor imaging--guided PET study with 11C-PK11195 in acute subcortical stroke. J Nucl Med 2010; 51: 1404–1412.
  50. Tiainen M, Mereroja A, Strabin D, Suvanto J, Curtze S, Linds berg PJ et al. Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke pa tients. Int J Stroke 2013; 8: 632–638.
  51. Wang L, Cao D, Wu H, Jia H, Yang C, Zhang L. Fisetin Prolon gs Therapy Window of Brain Ischemic Stroke Using Tissue Plasminogen Activator: A Double-Blind Randomized Place bo-Controlled Clinical Trial. Clin and Appl Thromb Hemost 2019; 25: 1–8.
  52. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack W. C-reactive protein in healthy subjects: associations with obesity, insu lin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972–978.
  53. Zhang J, Ren Q, Song Y, He M, Zeng Y, Liu Z et al. Prognostic role of neutrophil-lymphocyte ratio in patients with acute ischemic stroke. Medicine (Baltimore) 2017; 2017; 96(45): e8624
SUBMIT YOUR PAPER
Share
without publication fees
without publication fees
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications